What question did this study set out to answer?

To investigate the budgetary implications of GLP-1 agonist use among non-diabetic individuals covered by Medicare.

March 14, 2026

The Use of Glucagon‐Like Peptide 1 Agonists Among Non‐Diabetics: Evidence From Medicare Part D

Key Points

To investigate the budgetary implications of GLP-1 agonist use among non-diabetic individuals covered by Medicare.
Analyzed Medicare Part D data
Evaluated GLP-1 prescriptions
Assessed weight management coverage implications
Increased usage of GLP-1s observed among non-diabetics
Substantial budgetary pressures identified for Medicare
Ongoing policy discussions regarding expanded coverage of GLP-1s

Abstract

This growth underscores the substantial budgetary implications for Medicare, particularly amid ongoing policy discussions around expanding coverage of GLP-1s for weight management.

The Use of Glucagon‐Like Peptide 1 Agonists Among Non‐Diabetics: Evidence From Medicare Part D

Key Points

Abstract

Cite This Study

Also Consider

Also Consider